Latest Regulatory Approvals News

Loyal Metals has completed the acquisition of the Highway Reward Copper-Gold Project, clearing a major hurdle ahead of its A$79 million takeover by PT Bumi Resources. With shareholder approval secured, the scheme awaits final court endorsement.

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.

EQT Holdings has received a non-binding takeover proposal from BGH Capital valuing the company at $24.75 per share, subject to due diligence and regulatory approvals.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Apollo Minerals scored a legal win as the Administrative Court of Toulouse dismissed an NGO-led challenge that briefly stalled its Couflens tungsten project in France. The ruling removes an immediate obstacle, but an appeal window remains open.

Li-S Energy reported a reduced net loss of $4.9 million in FY26, propelled by major technological advances and a $7.8 million ARENA grant to scale manufacturing. The company secured key regulatory approvals and expanded strategic defence partnerships, positioning itself at the forefront of sovereign lithium sulfur battery supply.

Credit Corp has agreed to acquire HSBC Bank Australia's credit card run-off portfolio for about A$150 million, prompting a 10% uplift in FY27 NPAT guidance.

American Tungsten & Antimony Ltd (ASX: AT4) has kicked off critical wet table trials at its Del Sol Refinery in Nevada, moving closer to producing ammonium paratungstate and antimony flake from domestic sources. Engineering proposals for expanding the plant’s tungsten processing capacity are under review, while the company pursues US government funding and regulatory approvals.

James Hardie Industries has agreed to divest its European Fermacell sustainable walling and flooring business to Holcim for €840 million, while planning to close its European fiber cement operations and launch a $250 million share buyback.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

Finder Energy’s KTJ offshore development in Timor-Leste has achieved a key milestone with an independent classification of 22.2 million barrels of 2P reserves, underpinning its push toward a Final Investment Decision.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.